Select acquires remainder of subsidiaries
By Melissa Trudinger
Tuesday, 30 November, 2004
Tuesday, 30 November, 2004
Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.
The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.
Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.
Related News
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
